目的:探析罗格列酮钠在早期糖尿病肾病(DN)患者中的临床疗效及安全性. 方法:分析2015年3月~2017年1月在我院接受诊治的202例早期DN患者的临床资料.随机将入选者分成观察组(罗格列酮钠+替米沙坦)和对照组(替米沙坦)两组,每组101例.比较两组患者的一般资料、治疗前后的血糖及肾功能指标水平变化、临床疗效及不良反应发生率.结果:两组患者的基线资料无明显统计学差异.两组患者治疗后血糖及肾功能各指标水平均明显较治疗前低,且治疗后观察组患者血糖及肾功能各指标水平明显低于对照组.观察组患者的总有效率(96.0%)明显高于对照组(77.2%).两组患者的总不良反应发生率无明显统计学差异.结论:罗格列酮钠不但可以有效改善早期DN患者的血糖及肾功能,临床疗效突出,而且安全性良好,值得推广.%Objective Toanalyze the clicnial efficacy and safety of rosiglitazone sodium in early DN patients. Methods Clinical data of 202 patients with DNreceived treatment at our hospitalfrom March, 2015 to January, 2017 was retrospectively-analyzed. Patients included were divided into two groups at random, observe group (rosiglitazone sodium + telmisartan) and control group (telmisartan), 101 in each group. The general information, the blood glucose and renal function indexes before and after treatment, the clinical efficacy and the adverse occurrence rates in two groups were compared. Results The general infor-mation in two groups had no statistical difference. The blood glucose and renal function indexes after treatment in two groups were obviously lower than those before treatment, and the blood glucose and renal function indexes in observe group were obvi-ously lower than those in control group after treatment. The clinical efficacy in observe group (96.0%) was better than that in control group (77.2%). The adverse occurrence rates in two groups had no statistical difference. Conclusion The rosiglitazone sodium could significantly improve the blood glucose and renal function of early DN patients, the clinical efficacy is obvious, which is worth promoting.
展开▼
